
4th International Electronic Conference on Medicinal Chemistry
Part of the International Electronic Conference on Medicinal Chemistry series
1–30 Nov 2018
- Go to the Sessions
- Event Details
Welcome from the Chair
For the fourth year in a row, the International Electronic Conference on Medicinal Chemistry will be organized and sponsored by the peer-reviewed journal Pharmaceuticals, which is edited by MDPI. The conference will be held online at www.sciforum.net/conference/ecmc-4 during the month of November 2018.
The aim of the Conference is to gather researchers from all over the world and encourage discussions on any scientific field related to drug discovery and development. Posting presentations, videos, or posters disclosing your recent outstanding results enables you to take advantage of the conference to promote your work among thousands of your peers. Participation, as an author or a visitor, is ABSOLUTELY FREE; simply register on the home page.
This year, as the conference sponsor, Pharmaceuticals will be giving an award for the Best Presentation as elected by the scientific committee, which consists of 500 Swiss Francs. We hope you will be able to join this exciting event and enjoy a stimulating exchange with your peers around the world. Also, we will launch a Special Issue covering the event.
On behalf of our dynamic editorial staff and active scientific committee, we warmly invite you to join us during this fourth edition and we look forward to posting your contributions.
Conference Chair
Dr. Jean Jacques Vanden Eynde |
![]() |
Keynote Speakers

Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy of University of Porto, Portugal
Small molecules from the sea: models for innovative antimicrobial agents
medicinal chemistry; organic synthesis; heterocycles, P-glycoprotein; anticancer; anticoagulants; chiral drugs; marine natural products

Institut für Biochemie, Department für Chemie, Universität zu Köln, Zülpicher Straße 47, D-50674 Köln, Germany
Dr. Karsten Niefind is biochemist and apl. Professor at the Institute of Biochemistry of the University of Cologne. His research and teaching activities are dedicated to basic biochemistry and to the structure/function relationships of selected proteins, in particular involved in signal transduction and (plant) innate immune response or relevant for biotechnological applications.
structural biology; protein crystallography; enzymology; protein-protein interactions; protein kinases; EDS1-family of plant innate immune response proteins; human leukocyte elastase

Senior research fellow of the Latvian Institute of Organic Synthesis, Deputy Chairman, Division of Chemical, Biological and Medical Sciences, Latvian Academy of Sciences, Aizkraukles 21, Rīga, LV 1006, Latvia
Gunars Duburs Professor, Dr.chem.habil, Full Member of the Latvian Academy of sciences. Principal scientist, Latvian Institute of Organic Synthesis, Laboratory of Membrane active compounds and beta-diketones. Areas of activities: organic chemistry, medicinal chemistry. Scientific interests: chemistry of heterocyclic compounds, azines, membrane active compounds. Discovered and elaborated novel drugs: radioprotector diethone for oncological clinics, antihypertensive and antianginal drug riodipine (foridone), as well antioxidant diludine as carotene stabiliser and stimulant of productivity of animals. Publications: 550 scientific articles, 475 thesis, 75 patents.
heterocyclic chemistry (mainly partially hydrogenated azines: dihydro- (tetrahydro-) pyridines, pyrimidines, polycyclic derivatives) - studies of chemical, physical chemical and biological properties; medicinal chemistry (synthesis and studies of neurotro

Department of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences Via Ospedale 72, I-09124 Cagliari, Italy
medicinal chemistry; enzyme inhibitors; heterocyclic compounds, antiproliferative agents

Department of Oral Biology, University of Florida College of Dentistry, Gainesville, FL 32610, USA
host fungus interactions, antimicrobial peptides, antifungal peptides, defensins, cathelicidins

Department of Pathology & Microbiology University of Nebraska Medical Center, USA
Dr. Guangshun Wang is an Associate Professor at the University of Nebraska Medical Center (Omaha, Nebraska, USA). He is interested in developing novel compounds to treat human diseases, such as drug-resistant superbugs, viruses and cancer. His laboratory utilizes an integrated approach by combining chemistry, biophysics, bioinformatics, genetics, and structural biology. Two general methods are exploited to identify novel drug candidates. First, library screen is used. To search and screen starting templates, his laboratory has constructed the Antimicrobial Peptide Database (http://aps.unmc.edu/AP), which is widely utilized. As of July 2018, this database contained 2987 antibacterial, antiviral, antifungal, anti-parasitic and anticancer peptides, primarily from natural sources, covering the six life kingdoms (bacteria, archaea, fungi, protists, plants, and animals). Second, structure-based design is conducted. The lab uses multidimensional nuclear magnetic resonance (NMR) spectroscopy to determine the 3D structure of important pepti

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), PTS Granada, Av del Conocimiento 17, 18016 Granada, Spain
Dr. Alfredo Berzal-Herranz, Biologist. Senior Researcher at the Instituto de Parasitología y Biomedicina López-Neyra” belonging to the Spanish National Research Council (IPBLN-CSIC), Granada, Spain. In April 1990 obtained his Ph.D in Biochemistry and Molecular Biology from the Autónoma University of Madrid, Spain. After a short postdoctoral term at the BMC-Uppsala University (Sweden), he moved to the University of Vermont (USA; Dr. John Burke’s laboratory), where he was involved in the biochemical characterization of ribozymes. Since December 1993 he leads his own research group at the IPBLN-CSIC. He is the author of more than 80 scientific publications. His current scientific interest is the study of the biological activity of the RNA, mainly focusing in the structure/function of conserved functional RNA domains in viral RNA genomes (mainly HIV and HCV and flavivirus), and its potential as antiviral targets; design and characterization of RNA molecules with inhibitory activity (e.g. ribozymes, aptamers, antisense RNAs) a

School of Environmental Science and Engineering, Kochi University of Technology, Tosayamada, Kami, Kochi 782-8502, Japan
My name is Le Thi Song. My scientific research began in the area of Electrochemical and Corrosion Protection during my undergraduate studies at Department of Chemistry at Hanoi University of Science and Technology, Vietnam in 2009. From 2010 to 2012, I worked as master researcher at Interfacial Engineering Lab, Chemical and Biochemical Engineering Department at Dongguk University, Seoul, South Korea. Then in 2013, I became a Ph.D researcher at Kochi University of Technology, Japan under supervision of professor Nagatoshi Nishiwaki and received my Ph.D in organic synthesis in 2015. Then, I worked as a visiting researcher at this university for 1 year. From 2016, I became a research collaborator at Ton Duc Thang University in Vietnam. My research interests comprise not only synthetic organic chemistry using nitro compounds, heterocycles (ring transformation, dinitropyridone, nitroanilines, nitropyridines …), but also superhyrophobic coating, silica thin film, electroplating, corrosion and so on.

Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, US Department of Agriculture, Albany, California, USA.
Jong H. Kim is a Research Scientist in the Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, US Department of Agriculture, Albany, California, USA. His research focuses on the development of intervention strategies for control of fungal pathogens including mycotoxigenic fungi. He provides chemo-biological expertise, particularly in the identification of cellular targets, mechanisms of action and compound interaction, and participates in resistance management in collaboration with industry and academia.
antifungal; antioxidant system; cell wall integrity; chemosensitization; drug repurposing; drug resistance; filamentous fungi; mitochondrial respiration; mycotoxins; oxidative stress; redox-active; signaling pathway; small molecules; synergism; yeast path

Pharmacelera, Plaça Pau Vila, 1, Sector 1, Edificio Palau de Mar, Barcelona 08039, Spain
Dr. Alessandro Deplano is Pharmacelera’s Medicinal/Computational Chemist. He has got a Ph.D. in Medicinal Chemistry at the University of Cagliari, Italy, with a thesis entitled “Design, synthesis and SAR of small molecules acting on pain pathways” under the supervision of Prof. Valentina Onnis. His Ph.D. studies were focused on the design and synthesis of numerous molecules with different structure and specific pharmacological targets, in particular compounds endowed with analgesic activities. He worked also on synthesis of new molecules endowed with carbonic anhydrase inhibitory activity, antiproliferative activities on human cancer cell lines, and molecules endowed with nematicidal activity. He holds a Master degree in Pharmaceutical Chemistry and Technology, at University of Cagliari, which give him a strong background in pharmacology, biology and anatomy, along with organic and medicinal chemistry, field in which he gave his thesis dissertation. During his Ph.D. program he spent a semester at American University of Washington
Keynote Presentations
-
By
, -
Targeting the other genetic information coded by the viral RNA genomes
By
, , -
Discovery of novel endocannabinoid level modulators by modification of old analgesic drugs
By
, , -
Small molecules from the sea: models for innovative antimicrobial agents
By
, , , , , , , , -
High Efficiency Drug Repurposing for New Antifungal Agents
By
, , , , , , -
Field-based virtual screening: New trends to increase the chemical diversity of your leads
By
, , , , , -
By
, , , , , , , -
By
, -
By
, , , , , -
By
List of accepted submissions (75)
Id | Title | Authors | Presentation Video | Presentation Pdf | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-022476 | Antiviral effect of derivatives of triazoles on EBV-associated lymphoblastoid cells | , , , , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Epstein–Barr virus (EBV) causes lymphocyte-proliferative diseases, such as Burkitt’s lymphoma, Hodgkin’s lymphoma, other B and T cell lymphomas. Recently the connection between EBV and autoimmunity diseases has been demonstrated. In recent years, several studies have explored the concept that the compounds that have anti-herpetic activity might be able to influence the cell cycle of infected cells, by eliminating them from the body. However, cell cycle regulation during EBV-infection and the effect of anti-EBV drugs have received only limited attention. The aim of our work was to study derivatives of triazole (G14, G20, G22, and G24) as potential antiherpetic agent and their effect on the cell cycle of lymphoblastoid cell lines B95-8. According to PCR, anti-EBV activity was observed only for compounds G14 and G22, EC50 values were 27 and 100µg/ml. The В95-8 cells treated with all studied compounds were analyzed with the help of flow cytometry (cells were stained with propidium iodide). It was observed an induction of apoptosis in the presence of G22 at 700µg/ml; the proportion of apoptotic cells reached almost 40%. Other compounds G14 and G24 led to the switch of cells from the Sub G0 phase of the cell cycle to the G1 phase and subsequent activation of the S-phase. These compounds may play an important role as potential inducers of EBV lytic infection; with the addition of antiherpesvirus drugs, they could be therapeutically beneficial for EBV-associated tumors. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-022467 |
Biological activity of two new imidazole-based Cu(II) frameworks resulting from a one-pot reaction
, Mohammed S. M. Abdelbaky ,
Koray Sayın ,
,
Olufunso Abosede ,
Submitted: 20 Oct 2018 Abstract: Show Abstract |
,
Mohammed S. M. Abdelbaky ,
Koray Sayın ,
,
Olufunso Abosede ,
|
N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Imidazole occurs in most proteins as part of the side chain of histidine and constitutes a binding site for various transition metal ions in a large number of metalloproteins [1]. Consequently, the bonding between imidazole and transition metal ions is widely known [2] and of considerable interest especially in biological systems [3,4]. Consequently, copper(II)–imidazole systems with different ratios of imidazole to copper have been prepared and investigated by several researchers [5]. Moreover, being studied as models for copper proteins that contain both functionalities in the side chain [6], some mononuclear copper(II)–imidazole complexes with carboxylate ligands have been found to display a variety of pharmacological effects, including antitumor [7], superoxide dismutase and catecholase activities [8]. In order to contribute to the study of these systems, we have synthesized two new penta-coordinated copper(II) complexes with mixed-ligands, namely: imidazole and citric acid. The resulting compounds have shown remarkable antimicrobial and antifungal inhibition activities, which have been predicted by exploring the computational chemical reactivity of the two complexes [9].
References : [1] J. Reedijk & E. Bouwman, Bioinorganic Catalysis, Marcel Dekker Inc., New York & Basel, 1999. [2] K. D. Karlin & Z. Tyeklar, Bioinorganic Chemistry of Copper, Chapman & Hall, New York, 1993. [3] E. Colacio, M. Ghazi, R. Kivekäs, M. Klinga, F. Lloret & J. M. Moreno, Inorg. Chem, 2000, 39(13), 2770–2776. [4] M. T. Caudle, J. W. Kampf, M. L. Kirk, P. G. Rasmussen & V. L. Pecoraro, J. Am. Chem. Soc, 1997, 119(39), 9297–9298. [5] (a) S. M. Morehouse, A. Polychronopoulou & G. J. B. Williams, Inorg. Chem, 1980, 19(12), 3558–3561. (b) G. Fransson & B. K. S. Lundberg, Acta Chem. Scand. A, 1974, 28(5), 578–588. (c) D. L. McFadden, A. T. McPhail, C. D. Garner & F. E. Mabbs, J. Chem. Soc., Dalton Trans, 1976, 47–52. [6] H. Beinert, Coord. Chem. Rev, 1980, 33, 55. [7] J. R. J. Sorrenson, Prog. Med. Chem, 1989, 26, 437. (and references therein). [8] A. L. Abuhijleh & C. Woods, Inorg. Chim. Acta, 1993, 209, 187. [9] Direm, A. Abdelbaky, M. S. M. Sayın, K. Cornia, A. Abosede, O. & García-Granda, S. (2018). Inorg. Chim. Acta. 478. 59–70.
|
|||||||||||||||||||||||||||||||||||||||||
sciforum-022424 | Field-based virtual screening: New trends to increase the chemical diversity of your leads | , , , , , |
![]() |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Computational chemistry methods can significantly reduce experimental costs in early stages of a drug development project by filtering out unsuitable candidates and discovering new chemical matter. Molecular alignment is a key pre-requisite for 3D similarity evaluation between compounds and pharmacophore elucidation. Relying on the hypothesis that the variation in maximal achievable binding affinity for an optimized drug-like molecule is largely due to desolvation, we explore herein a novel small molecule 3D alignment strategy that exploits the partitioning of molecular hydrophobicity into atomic contributions in conjunction with information about the distribution of hydrogen-bond donor/acceptor groups in each compound. A brief description of the method, as implemented in the software package PharmScreen, is presented. The computational procedure is calibrated by using a dataset of 402 molecules pertaining to 14 distinct targets taken from the literature and validated against the CCDC AstraZeneca test set of 121 experimentally derived molecular overlays. The results confirm the suitability of MST based-hydrophobic parameters for generating molecular overlays with correct predictions obtained for 100%, 93%, and 55% of the molecules classified into easy, moderate and hard sets, respectively. The potential of this tool in a drug discovery campaign is then evaluated in a retrospective study with the aim to evaluate the correlations between activities and similarity score of a series of sigma-1 receptor ligands. The results confirm the suitability of the tool for Drug Discovery purposes finding the 67% of the most active ligands (≤10 nM) in Q1 of the ranking and the most active compound in position five. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-022124 | Study of physicochemical and pharmacokinetic properties of flavonoids from Euterpe oleracea Martius | , , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Aims: Neurodegenerative disorders prevalence is growing due to life expectancy increase, thus the passage signs of time are clearly visible in the brain. Oxidative stress is a factor that contributes to the organic defenses imbalance, producing free radicals, brain-aging progression and various degenerative diseases. Macromolecules oxidative damage increases with age, leading to a progressive decline in cell and tissue function. Antioxidants reduce these free radicals formation or react with them by neutralizing them. Euterpe oleracea Martius, popularly known as açaí, is rich in α-tocopherol, fibers, lipids, polyphenols and mineral ions. Believes that polyphenols high content, among which flavonoids, confers to açaí fruits a variety of health promoting effects, including anti-inflammatory, immunomodulatory, antinociceptive and antioxidant properties. The present study aims to analyze, in silico, flavonoids physicochemical, pharmacokinetic and toxicological properties present in Euterpe oleracea Martius. Place and Duration of Study: Pharmaceutical and Medicinal Chemistry Laboratory (PharMedChem) at Amapá Federal University (UNIFAP), Macapá, Brazil, between December 2017 and January 2018. Methodology: Initially, selected 16 molecules present in Euterpe oleracea Martius, divided into açaí pulp and oil. The physicochemical properties of the flavonoids were analyzed by the rule of 5, pharmacokinetic properties in the QikProp module of the Schrödinger software and the toxicity profile using the DEREK program. Results: Among physical-chemical properties, the flavonoid compounds catechin, epicatechin, luteolin, chrisoeriol, taxifolin, apigenin, dihydrocaempferol, isovitexin and vitexin presented good oral bioavailability. In pharmacokinetic properties, the molecules catechin, epicatechin, isovitexin, luteolin, chrisoeriol, taxifolina and isorhamnetina rutinosídeo presented the best results and high human oral absorption. In toxicological properties prediction the compounds presented good results, except for the isorhamnetina rutinoside and rutin compounds that presented alert about the mutagenicity for hydroxynaphthalene or derivative. Conclusion: Catechin, chrysoerythol and taxifolin flavonoids presented the best results, but other computational and experimental methods are needed to identify these compounds biological activity. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-022167 | A Practical Access to New Pyrazole SKF-96365 Analogues as Potential Store-Operated Calcium Entry (SOCE) Inhibitors | , , , , , , , | N/A |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||
The racemic synthesis in four steps of pyrazole SKF-96365 analogues without substituent (CF3 group) on the pyrazole platform was realized in moderate to good yields. The separation of (±) hydroxyl enantiomers 4 was developed successfully using the method of "half-concentration" with commercial (+)-(1S)- and (-)-(1R)-10-camphorsulfonic acid (CSA) followed by neutralization of diastereomers with MeONa in dry MeOH solution. With the pure enantiomers (-)-(1S)-4b and (+)-(1R)-4b, initial attempts to obtain the crystallized (-)-(1S)-7d and (+)-(1R)-7d after treatment of intermediate 6d with a solution of 1M HCl (for precipitation of hydrochloride salt 7d) failed. We have also investigated the effects of compounds 7(a-d) on endoplasmic reticulum (ER) Ca2+ and SOCE on PLP-B lymphocyte cell line and compound 7d was identified as a better SOCE inhibitor than SKF-96365. This preliminary SAR study showed that the MeO group in para-position of the phenethyl-1H-pyrazolium skeleton or for the Cbeta-phenylpropoxy side chain of 7 influenced the SOCE activity. |
Event Awards
The Awards
This year, as a sponsor, Pharmaceuticals would like to award the best presentation as elected by the members of the scientific committee. The Award will consist of 500 Swiss Francs. We look forward to posting your contributions.
Terms and Conditions:
- Full PPT presentation must be submitted to ECMC-4.
- The quality of the presentation.
- The scientific content of the presentation
Evaluation
- Each Evaluation Committee member will give an assessment for each applicant in terms of the criteria outlined above.
- Total score for each presentation will be ranked, from highest to lowest.
- If two or more students get the same score, further evaluation will be carried out.
- All decisions made by the Evaluation Committee are final.
Best Presentation at ECMC-4
Pharmaceuticals and the Organizing Committee of ECMC-4 congratulate Valentina Barcherini, Margarida Espadinha, Joana Soares, Sara Gomes, Alexandra Antunes, Lucília Saraiva, Maria Santos who received an award for the best presentation at ECMC-4:
Topic: Enantiopure oxazoloisoindolinones: Promising small molecules for p53-based therapy with potential anticancer properties
authored by Valentina Barcherini, Margarida Espadinha, Joana Soares, Sara Gomes, Alexandra Antunes, Lucília Saraiva, Maria Santos
![]() |
"Valentina Barcherini is a second-year PhD student at M.M.M. Santos’ team (Faculty of Pharmacy, University of Lisbon) and member of the Medicinal Chemistry group of the Research Institute for Medicines, iMed.ULisboa. Valentina’s doctoral research is centred on the development of novel small molecules that act as dual p53-MDM2/X protein-protein interactions inhibitors. Valentina holds a master’s degree in Bioorganic Chemistry from the New University of Lisbon, Portugal. Previously, she graduated in Applied Chemistry in University of Padova (Italy)."
Conference Chairs

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium
[email protected]
Conference Committee

Formerly professor at the Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium

Università degli Studi di Cagliari, Dipartimento di Scienze Chimiche e Geologiche, Cittadella Universitaria, SS 554, bivio per Sestu, 09042, Monserrato (CA), Italy

Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA

Faculté de Pharmacie, Université Libre de Bruxelles, Campus Plaine CP 205/5, 1050 Brussels, Belgium

PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Corrensstr. 48, 48149, Muenster, Germany

Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal

School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152−160 Pearse Street, Dublin 2 D02 R590, Ireland

Universidade Federal do Rio de Janeiro, IPPN, CCS, Bloco H - Ilha do Fundão, Rio de Janeiro, RJ - 21941-902, Brazil

School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, Norfolk NR4 7TJ, UK

Normandie Univ, Univ Rouen; INSA Rouen, CNRS, Laboratoire COBRA UMR6014, Bâtiment IRCOF, 1 rue Tesnière, F-76821 Mont Saint-Aignan Cedex, France
Call for Papers
The members of the scientific committee are pleased to announce the Call for Papers for the 4th International Electronic Conference on Medicinal Chemistry and to invite each researcher working in that exciting field of science to share his/her recent results with his/her colleagues around the world.
The conference will cover a wide range of aspects involved in drug discovery and development. A non exhaustive list of topics that will be considered comprises:
- ADMET
- Animal experimentation
- Assay development
- Biomarkers
- Biomolecules
- Biosensors
- Biotechnology
- Chemical synthesis
- Clinical studies and side effects reports
- Combinatorial chemistry
- Drug delivery (including bioconjugates and prodrugs)
- High throughput screening
- Hit identification
- Imaging techniques
- In silico experiments
- In vitro studies
- Lead optimization
- Omics
- Pharmaceutical analysis
- Scale-up
- Structure–activity relationships
- Target selection
Participation at the 4th International Electronic Conference on Medicinal Chemistry is absolutely free of charge for contributors and visitors. Researchers are invited to provide a short abstract on line at https://www.sciforum.net/login from now until October 25, 2018. Acceptance will be notified within a week after submission of the abstract. Then the author(s) will be asked to present their work (in English) in the form of a slide show (or a video) using the template provided by the conference (see Instructions for Authors). Posters, realized following the template provided online, will also be considered. All accepted submissions will be displayed online, at www.sciforum.net/conference/ecmc-4, on November 1-30, 2018.
Authors of the most outstanding contributions, as selected by the Scientific Committee, will be invited to publish their work as a research article free of charge or at a discounted price, in a Special Issue of the journal Pharmaceuticals.
The Scientific Committee looks forward to receiving contributions in response to this call and will be glad to provide any further information to interested parties. Questions may be addressed to the chairman via e-mail at [email protected] or to the Pharmaceuticals editorial office at [email protected].
We thank you in advance for your attendance of this conference and look forward to a stimulating exchange.
Instructions for Authors
Submissions should be done by the authors online by registering with www.sciforum.net, and using the "Start New Submission" function once logged into system.
Researchers interested in attending the conference must submit, on this website and not later than 25 October 2018, an abstract of the work they intend to present.
After the abstract is accepted by the Scientific Committee (1-5 days after receipt of the abstract), the authors will be invited to prepare a full description of their work preferably under the form of a PowerPoint presentation, and to upload it before 30 October 2018 to ensure final check.
The presentations will be accessible on https://www.sciforum.net/conference/ecmc-4 during the time of the conference.
Authors are encouraged to prepare a presentation using the template provided by the Conference. Slides will be displayed directly in the website using Sciforum.net's proprietary slides viewer. They can be prepared in exactly the same way as for any traditional conference where research results can be presented. Slides should be converted to the PDF format before submission so that our process can easily and automatically convert them for online displaying.
Electronic Conference on Medicinal Chemistry PPT template file
Electronic Conference on Medicinal Chemistry Poster template file
The following organization is recommended for your presentation:
- Length of the presentation: no more than 30 slides
- Slide 1 (strictly one slide): Title, Authors’ names, Affiliation(s), email address of the corresponding Author, and, not mandatory, logos of the laboratory and/or institution;
- Slide 2 (strictly one slide): Graphical Abstract, repeat the title of the presentation but avoid other text as far as possible;
- Slide 3 (strictly one slide): Abstract (max 200 words) and 3-5 keywords separated by semicolons;
- Slide 4 and following slides: should contain (in the given sequence) Introduction, Results and Discussion; Conclusions.
- Last slide: Acknowledgments and, not mandatory, logos of sponsors of the work.
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their research works. Hence, by submitting a contribution to this conference, the authors retain the copyright of their contribution, but they grant MDPI AG the non-exclusive right to publish this contribution online on the Sciforum.net platform. This means the authors can easily submit their contribution to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their research works. Hence, by submitting a contribution to this conference, the authors retain the copyright of their contribution, but they grant MDPI AG the non-exclusive right to publish this contribution online on the Sciforum.net platform. This means the authors can easily submit their contribution to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Sponsors
Exhibition Hall

woohooo
Euriso-top Founded in January 1991 by a group of researchers from the Commissariat à l'Energie Atomique (CEA), Euriso-Top became a leading producer of deuterated solvents and stable isotope labelled compounds in Europe, thanks to an incomparable knowledge.
Read more...With a large catalog of thousands of chemical compounds covering various fields of application (Proteomics and Genomic research, Biotechnology discovery, Organic synthesis, Pharmaceutical development, Manufacturing industry), Euriso-top, has been supplying for 25 years the scientific community with stable isotope labeled chemicals, isotopic gases, NMR solvents, isotopic metals, Clinical trials substrates.
ELVESYS is an innovative self-funded company that started the commercialization of microfluidic instrumentation in 2011. ELVESYS aims to become a key research partner in the microfluidic field because we believe this domain will be the heart of next technological revolution.
Read more...Doubling its turnover every 9 months, in just 4 years its ELVEFLOW brand has become the world leader of high performance microfluidic flow control. Rewarded by more than 10 entrepreneurial distinctions, ELVESYS launched two sisters companies in 2013 and 2014, respectively specialized in the biological environment control, the microfluidic device design and fast microchip prototyping.
Hielscher Ultrasonics GmbH: High-power ultrasonic processors for liquid processing
Hielscher Ultrasonics specializes in the design, development and production of ultrasonic devices - both for use in laboratories as well as for industrial applications. Due to the outstanding power of the ultrasonic processors and the high quality standards, Hielscher became the world's leading supplier of high performance ultrasonic equipment. The product range of Hielscher Ultrasonics includes ultrasonic devices to / for
Read more...- Dispersing
- Synthesis of nanoparticles
- Desaggregieren / Disagglomerating
- Particle Size Reduction (Wet-milling / fine-grinding of micro-and nano-scale particles)
- Homogenization
- Emulsification
- Extraction
- acceleration of chemical reactions (Sonochemistry)
- Wire cleaning
Precision NanoSystems (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI headquarters is located in Vancouver, Canada with scientist and sales support located globally and our instruments in over 20 countries.
Read more...PNI’s proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit https://www.precisionnanosystems.com
A leading Belgian company distributing laboratory instruments and furniture.
As a distributor of laboratory instruments and lab furniture, Analis is primarily oriented towards research activities, biotechnology applications, chemistry, clinical chemistry and medical in vitro diagnostics and quality control.
Read more...We are actively involved in the biotechnological and pharmaceutical sector (from basic research to production), as well as in the agro and food industry. Our mission is to provide researchers in proteomics, genetics and cellular analysis with appropriate professional instruments and support tools.
Established in Namur in 1927, Analis employs more than 130 people in two locations: The head office is in Suarlée (NAMUR) in the south of Belgium and we have a branch office in Sint-Denijs-Westrem (GENT) in the north.
Thanks to acquisitions, distribution activities and constant innovation, our company has grown and integrated new technologies. Analis covers all aspects of laboratory management: from laboratory project design to complete maintenance of customer’s installed equipment. We structured our organization in order to guide each (research) laboratory with the necessary expertise, application support, technologies and solutions in the following fields: Life Sciences;- In Vitro Diagnostics; Laboratory Equipment; Analytical Chemistry; Materials Testing; Metrology; Laboratory Furniture by ARDESTA.
Our priority is to offer a high level of application and service support. Furthermore, by offering a full range of flexible automation systems, we help each laboratory to increase its lab productivity.
Analis is certified ISO9001-2008, including conception, production, distribution and technical assistance.
Analis also runs a research laboratory, ‘Analis R&D Diag’, that develops electrophoresis and CE in vitro diagnostic kits (CEOfix™). ANALIS R&D Diag is focused on analytical method development through the use of capillary
In the field of industrial applications for microwaves assisted green chemistry there are many microwave applications, chemical synthesis, extraction or other applications. The benefits of microwaves assisted green chemistry are, for the most part, improved quality of the final products like minimized thermal degradation due to the spreed of the process and spectacular reduction in process timing and footprint. Microwaves are used to heat a product quicker than conventional processes. We obtain a better quality product.
MDPI (Multidisciplinary Digital Publishing Institute) is an academic open-access publisher with headquarters in Basel, Switzerland. Additional offices are located in Beijing and Wuhan (China), Barcelona (Spain) as well as in Belgrade (Serbia).
Read more...MDPI publishes 179 diverse peer-reviewed, scientific, open access, electronic journals, including Molecules (launched in 1996; Impact Factor 2.861), the International Journal of Molecular Sciences (launched in 2000; Impact Factor 3.226), Sensors (launched in 2001; Impact Factor 2.677), Marine Drugs (launched in 2003; Impact Factor 3.503), Energies (launched in 2008; Impact Factor 2.262), the International Journal of Environmental Research and Public Health (launched in 2004; Impact Factor 2.101), Viruses (launched in 2009; Impact Factor 3.465), Remote Sensing (launched in 2009; Impact Factor 3.244), Toxins (launched in 2009; Impact Factor 3.030), Nutrients (launched in 2009; Impact Factor 3.550), and Pharmaceuticals (CiteScore 4.9). Our publishing activities are supported by more than 15,700 active scientists and academic editors on our journals' international editorial boards, including several Nobelists. More than 263,500 individual authors have already published with MDPI. MDPI.com receives more than 8.4 million monthly webpage views.
Tropical Medicine and Infectious Disease (ISSN 2414-6366) is an international, scientific, open access journal of tropical medicine and infectious disease published quarterly online by MDPI. It is the official journal of The Australasian College of Tropical Medicine.
Simulations Plus, Inc. (NASDAQ: SLP) is the premier developer of modeling & simulation solutions supporting drug discovery and development research and regulatory submissions. We partner with clients to provide a ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval.
Read more...With our subsidiary companies, Cognigen Corporation and DILIsym Services, we also offer #1-ranked, easy-to-use software (GastroPlus™, ADMET Predictor™, KIWI™, DILIsym®, NAFLDsym®, and PKPlus™) to bridge data mining, compound library screening with QSAR models, PBPK modeling & simulation in animals and humans following intravenous, oral/oral cavity, ocular, inhalation, dermal, and intramuscular administration, and quantitative systems pharmacology approaches. When difficult answers are hard to find, the end-to-end solutions from Simulations Plus can help.
All the latest news, products, jobs, events and much more pertaining to chemistry, life science and analytics can be found on the CHEMIE.DE online portals. bionity.com is our life science flagship. It addresses readers who are interested in facts and trends from life science, biotechnology and pharma—and all this in four different languages! A total of around 700,000 page views per month confirm there is great interest in bionity.com and its information services.
Pharmaceuticals (ISSN 1424-8247; CODEN: PHARH2) is an open access journal of medicinal chemistry and related drug sciences, published quarterly online by MDPI. Citations are available in PubMed, full-text archived in PubMed Central. Following Scopus, the 3-year *CiteScore* of Pharmaceuticals is 4.9 in 2016. Pharmaceuticals is now ranked #8/168 in the category "Pharmaceuticals Science".
LATOXAN is the leading producer of venoms from snakes, scorpions and batrachians with over 300 different venoms worldwide available. LATOXAN also produces and supplies venom toxins, plant, plant small molecules and screening libraries. LATOXAN supplies Pharmaceutical Industry, Academic and Pharma Research centres and worldwide distributors of Life Science Reagents.
B. Posters
Show all published submissions (19) Hide published submissions (19)
Submissions
List of Papers (19) Toggle list